Biotech firms raise record funds in 2026, with $2.1 bn round for Isomorphic Labs

After a few slow years, the biotech financing landscape is showing signs of recovery, though investors remain cautious about where they place capital.

A recent PharmaVoice reader poll found that 28% of respondents view the ease of fundraising as the top indicator of market health, and Dr. Alexander Gebauer of Galimedix Therapeutics noted that many companies still face fundraising challenges.

Venture capital investment in biotech totaled $7.94 billion in the first quarter of 2026, slightly down from $8.04 billion in the fourth quarter of 2025, reflecting a steady but selective flow of money.

Even in this measured environment, some firms secured large rounds, highlighted by Isomorphic Labs' $2.1 billion Series B in May, marking its second major external funding event.